Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

10.32 -0.41 (-3.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Demystifying Prothena Corp: Insights From 6 Analyst Reviews ↗
 
Via Benzinga
News headline image
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease ↗
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients. 
Via Investor's Business Daily
News headline image
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits ↗
Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses. 
Via Benzinga
News headline image
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
From Prothena Corporation plc
Via Business Wire
News headline image
Expert Ratings For Prothena Corp ↗
 
Via Benzinga
News headline image
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Earnings Preview For Prothena Corp ↗
 
Via Benzinga
News headline image
Prothena to Report Third Quarter 2024 Financial Results on November 12
From Prothena Corporation plc
Via Business Wire
News headline image
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Breaking Down Prothena Corp: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Demystifying Prothena Corp: Insights From 8 Analyst Reviews ↗
 
Via Benzinga
News headline image
Dow Dips 300 Points; Emcore Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher ↗
 
Via Benzinga
News headline image
Prothena Announces Leadership Team Updates
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
News headline image
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024 ↗
PRTA stock results show that Prothena Corp beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Second Quarter 2024 Financial Results on August 8
From Prothena Corporation plc
Via Business Wire
News headline image
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win ↗
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
News headline image
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
From Prothena Corporation plc
Via Business Wire
News headline image
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024 ↗
PRTA stock results show that Prothena Corp missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report First Quarter 2024 Financial Results on May 8
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
From Prothena Corporation plc
Via Business Wire
News headline image
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
News headline image
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Appoints David Ford to Newly Created Chief People Officer Position
From Prothena Corporation plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.